MoneyWorks4Me

Medicamen Biotech - Quaterly Results

08 Feb 2022 Evaluate
Revenue showed a marginal decline at Rs. 326.41 millions. For the quarter ended December 2021, as compared to corresponding quarter of last year.A good growth in profit of 25.31% reported to Rs. 37.78  millions over Rs. 30.15 millions of corresponding previous quarter.The company reported a good operating profit of 71.36 millions compared to 52.56 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 326.41 329.22 -0.85 926.91 898.09 3.21 1101.46 1173.42 -6.13
Other Income 8.27 0.01 82600.00 13.82 2.17 536.87 7.54 19.09 -60.50
PBIDT 71.36 52.56 35.77 199.58 149.18 33.78 203.35 196.71 3.38
Interest 4.93 0.87 466.67 8.37 7.05 18.72 10.64 5.68 87.32
PBDT 66.43 51.69 28.52 191.21 142.13 34.53 192.71 191.03 0.88
Depreciation 15.67 7.14 119.47 42.47 21.05 101.76 25.20 24.99 0.84
PBT 50.76 44.55 13.94 148.74 121.08 22.84 167.51 166.04 0.89
TAX 12.98 14.40 -9.86 27.23 37.64 -27.66 42.65 43.45 -1.84
Deferred Tax -2.54 0.28 -1007.14 -7.19 0.69 -1142.03 1.19 -2.50 -147.60
PAT 37.78 30.15 25.31 121.51 83.44 45.63 124.86 122.59 1.85
Equity 122.17 122.17 0.00 122.17 122.17 0.00 122.17 122.17 0.00
PBIDTM(%) 21.86 15.97 36.94 21.53 16.61 29.63 18.46 16.76 10.13
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..